GERN as of Nov 1 · 17:33 ET
GERNNasdaqPharmaceutical Preparations
Geron Corp · Brief
Next report
3 days
Nov 4 · before openest.Q3 FY26
Expected move
Inputs1 of 8≥ implied
- avg implied
- ±19.8%
- avg realized
- ±8.8%
Aug 8 '24±8.4%▲+0.88%×0.10
Nov 7 '24±16.0%▲+0.47%×0.03
Feb 26 '25±17.0%▼−32.07%×1.89
May 7 '25±29.5%▼−0.76%×0.03
Aug 6 '25±28.3%▲+15.83%×0.56
Q3 FY25±22.6%▼−5.22%×0.23
Q1 FY26±23.0%▼−11.79%×0.51
Q2 FY26±13.3%▼−3.68%×0.28
quarterimplied−35%0+35%realized×
Q2 FY26±13.3%▼−3.68%×0.28
Q1 FY26±23.0%▼−11.79%×0.51
Q3 FY25±22.6%▼−5.22%×0.23
Aug '25±28.3%▲+15.83%×0.56
May '25±29.5%▼−0.76%×0.03
Feb '25±17.0%▼−32.07%×1.89
2 older reports
Nov '24±16.0%▲+0.47%×0.03
Aug '24±8.4%▲+0.88%×0.10
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close
Bull & bear
Nov 4 report · est.Bull2 of 3
Bear2
0.26%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case
Linked exposure
GERN report sessionNo linked exposure.
Your note
privateThesis 0 · Decisions 0 · Observations 0
No thesis.